Follicular Lymphoma

SCI member @AshAlizadeh & others provide the first direct evidence for the presence of genetic alterations in circulating precursor cells years before overt #FollicularLymphoma development, dominated by CREBBP mutations within the KAT domain. https://t.co/dHkXrUJKIQ #lymsm (@SCIDirector)

Can you do follicular lymphoma next? And also, can you plz wave a magic wand so that the USA guidelines are acknowledged and followed in Canada? Asking for a friend… (@MGregoryAuthor)

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma https://t.co/u7ixzHC9qm via @onclive (@VivekSubbiah)

@CwynKate @WilsonAndrewDr Australian-first Leverage follicular lymphoma drug trial offers hope to patients with incurable cancer https://t.co/QYR8WHP93b via @ABCaustralia (@FeliciaJCox)

You got this Dr. Debster! Glad you caught it early and a cream will put it in remission. I am a survivor of follicular lymphoma (@DDStoup)

Follicular lymphoma (FL), a rare blood cancer of the lymphatic system, is one type of non-Hodgkin lymphoma. To learn more about follicular lymphoma, MyLymphomaTeam spoke with hematologist @timfenske. Watch some of his insights:https://t.co/7mr4ulWUpQ (@MyLymphomaTeam)

👉 No, except Stage 1A disease treated with radiotherapy. ☢️ can be curative in 😷s with localized follicular lymphoma, with historical series showing a 10-year disease-free survival of 40 to 50%. (@Dr_MSU)

Is follicular lymphoma #lymsm curable? https://t.co/0YQSaZSf5D #17icml @SWOG (@HayderSaeed_MD)

Pleased to share @fredhutch results of #venetoclax and #ibrutinib in relapsed follicular lymphoma at #17ICML. #Zanubrutinib Rosewood study update also supports use of #BTK inhibitor in FL. @Rcl14L @mshadman @KatieLaiMD_MPH @DunleavyKieron #lymsm #17ICML (@UjjaniC)

Congrats to Dr Silvana Novelli! 👏👏👏 (from @hematosantpau) Impressive results with the bispecific (CD20xCD3) Ab Odronextamab in r/r follicular lymphoma #17ICML (@Fer_martinmoro)

Follicular lymphoma chaired by Eva Kimby and @DrJFriedberg. Starting with “functional cure” for FL. Hopeful for FL patients. #17ICML (@Dr_Daniel_Molin)

Very illustrative meet the expert session about follicular lymphoma, by @DrJFriedberg One of the final messages: ‘Chemoimmunotherapy + ASCT is able to cure a substantial subset of r/r patients’ #17ICML (@Fer_martinmoro)

Between CART, bispecific antibody approaches, and tweaking regimens / dosing of the whole FL therapy “toolbox”, we may already be achieving cure for certain #follicularlymphoma patients - excellent morning session by @DrJFriedberg #17ICML @Cure_FL (@ZozoMousse)

Glofitamab has been approved by the FDA for DLBCL, NOS or transformed follicular lymphoma after 2 lines of therapy. A fixed- duration therapy for patients! Suspect it will become a post-CAR option in sequencing. #lymsm #17ICML https://t.co/UKVJLHHLuw (@majorajay)

@LNastoupilMD @Jessica_Okosun @WomenInLymphoma #follicularlymphoma (@WomenInLymphoma)

Day 4 @icmlugano #ICML2023 Oral presentation A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15-YEAR FOLLOW-UP OF PHASE III SWOG-S0016 https://t.co/kkfOg8fEGp @SWOG @DrJFriedberg @fredhutch @SoniSmithMD (@mshadman)

Can we cure #follicularlymphoma? At #17ICML, @LNastoupilMD highlights long-known impact of #TME, but new tech finally hints at cellular imm determinants. Pointing to @BCD_AACR article from @GreenLymphoLab classifying FL by #singlecell microenv't profiling: https://t.co/L27E24MeCD (@DaveGennert)

Check out the multi-institutional effort to characterize GI follicular lymphoma presented by Frederiquie St-Pierre #17ICML (@AsaadTrabolsi)

@mshadman sharing the impressive results of MB-106 #CART in follicular #lymphoma from @fredhutch at #17ICML (@UjjaniC)

FOLLICULAR LYMPHOMA PATIENT-DERIVED ORGANOIDS FOR BISPECIFIC T-CELL ENGAGER IMMUNOTHERAPY @schroersmartin @Jkastens_phd @max_diehn @lisa_wagar https://t.co/LqIjx9Vy5A (@AshAlizadeh)

.@DrJFriedberg introduces the @SWOG S2308 as a trial that asks: “can we cure follicular lymphoma? Not long ago it would have been unheard of to ask that question from this podium.” #17ICML (@Eddie_Cliff)

Great to start #17ICML with @DrJFriedberg on follicular lymphoma - BM biopsy is largely useless - POD24 main useful prognostic marker - some patients likely cured - R2 an attractive ‘chemo-free’ option #lymsm (@Eddie_Cliff)

#17ICML let’s start this morning with JW Friedberg MD, talking about follicular lymphoma in meet the expert. @GuiperiniMD @Denicasuri (@hematologo)

Here we go! Starting this morning at #17ICML in the meet the expert session with Dr. @DrJFriedberg about follicular lymphoma. Follow the live tweets in this thread! #lymsm (@majorajay)

Catching up on news from the 2023 @ASCO Annual Meeting? Don't miss this video featuring @chadinabhan interviewing @drsarahruth of @WCMLymphoma about her #ASCO2023 presentation on the impact of imaging frequency in follicular lymphoma trials. 📺: https://t.co/DepqHLXe55 (@Blood_Cancers)

Four legends at this round table . @JudithTrotman1 @DrMatasar @graham74GC and Dr. Hüber. Talking about bispecifics for follicular lymphoma beyond 2L. (@hematologo)

🛫to Lugano. Nice to be back in person for #17ICML to hear the latest advances in #lymphoma. Looking forward to seeing the @Cure_FL team and speaking at this session: 'What will it take to cure follicular lymphoma'. Fab panel: @LNastoupilMD @LabMelnick #marcoladetto #lymsm (@Jessica_Okosun)

It’s not too late to register for this patient education program! @WeillCornell’s Dr. Sarah Rutherford (@DrSarahRuth) will be speaking at @CancerCare’s #workshop about follicular #lymphoma. Register to join the teleconference: https://t.co/jgOn5vPkZL (@WCMLymphoma)

Wrapped up our second day of interviews here at #EHA2023 with @mshadman (@fredhutch), who spoke on MB-106 in patients with Waldenström's macroglobulinemia & follicular lymphoma, the SEQUOIA trial & more! Check out our coverage here: 👉 https://t.co/2U3kjqJyaP @EHA_Hematology (@VJHemOnc)

Can't wait for #17ICML next week - @Cure_FL will be hosting a Satellite Symposium 'What will it take to cure follicular lymphoma'. Get ready for an incredible line-up of speakers including @Jessica_Okosun @LNastoupilMD. If you're attending @icmlugano don't miss out on this event! (@JuliePDodds)

My mentor @AnnaSureda5 is talking about epcoritamab + lenalidomide + Rituximab en Follicular Lymphoma. #EHA2023 (@hematologo)

Low Vit D Assoc w/ Inferior Survival in Follicular NHL: #SWOGOnc & LYSA Studies [2015] Kelly et al. @JCO_ASCO https://t.co/XMkXxlbee2 #lymsm #BoneHealth (@mtmdphd)

Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular #lymphoma : A subset analysis of the FOLL12 trial by ⁦@FIL_ETS⁩ - Nizzoli - Hematological Oncology - ⁦@StefanoLuminari⁩ ⁦ https://t.co/PgHIiu3LUC (@frbertoni)

From the June issue— Founder mutations in #follicularlymphoma precursors, by @schroersmartin, Joanne Soo, @gabriel_brisou, @FSchererMD, Bertrand Nadel, @SRoulland, @max_diehn, @AshAlizadeh et al. https://t.co/GjioWYOslA @CIML_Immunology @StanfordCancer (@CD_AACR)

At the #ASCO23 #Lymphoma Session? ICYMI in @CD_AACR: Tracing Founder Mutations in Circulating & Tissue-resident #FollicularLymphoma Precursors by @schroersmartin Joanne Soo @gabriel_brisou @FSchererMD Bertrand Nadel @SRoulland @max_diehn @AshAlizadeh et al https://t.co/TEIj4kRyFB (@ElizSMcKenna)

Thanks to @drsarahruth of @WCMLymphoma for stopping by to chat with @chadinabhan about her #ASCO23 presentation on follicular lymphoma! Stay tuned for the video interview! (@Blood_Cancers)

Want to learn more about follicular #lymphoma treatments? Our own expert Dr. Sarah Rutherford (@drsarahruth) is speaking at @CancerCare’s patient education #workshop on June 14. Sign up: https://t.co/jgOn5vPkZL (@WCMLymphoma)

3 Follicular lymphoma In acut promyelocytic leukemia there is bruising easily and bleeding gum In CLL there is anaemia and Bleeding or bruising In Mental cell there is tonsils enlargement and hepatomegaly In CML patient having a high temperature, and feeling hot or shivery (@kissinger_Mo)

1. Sharon Lazzaroni Study Coordinator at Townsville who along with Joel Wight (and I believe a little help from John Casey) has recruited 10 patients to PETReA 1L Follicular Lymphoma study. Matching @annamjohnston2 and UK #NCRI @tobyeyre82 pro-rata! (@JudithTrotman1)

#Hematology Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden #Follicular #Lymphoma: Results of a LYSA Study | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #lymsm https://t.co/zoXR38QKbD (@DrRaulCordoba)

Recurrent Follicular Lymphoma https://t.co/NoL097w2jH #lymsm #lymphoma @MayoClinic @MayoCancerCare @LNastoupilMD @MDAndersonNews @gilles_salles @MSKCancerCenter @WeillCornell (@ASCOPost)

TNB-486 = AZD0486 (CD19 x CD3 T-cell engager, ex Teneobio). $AZN presenting ph1 follicular lymphoma data at #EHA23 (@JacobPlieth)